Dr. Dalton on Novel Approaches in Uterine Cancer

Heather Dalton, MD
Published: Tuesday, Apr 18, 2017



Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses novel approaches emerging in the field of uterine cancer.

In the uterine cancer field, there have been changes coming over the last few years as researchers are learning more about microsatellite instability (MSI), which is present in select patients with uterine cancers. Additionally, this MSI may be targeted with the use of PD-1 inhibitors, Dalton adds.

Another tumor that is known to be MSI-high includes colorectal cancer, she explains. In the gynecologic field, uterine cancers seem to be the tumor type that have MSI-high characteristics. However, early research suggest that some ovarian cancers may have this, as well.


Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses novel approaches emerging in the field of uterine cancer.

In the uterine cancer field, there have been changes coming over the last few years as researchers are learning more about microsatellite instability (MSI), which is present in select patients with uterine cancers. Additionally, this MSI may be targeted with the use of PD-1 inhibitors, Dalton adds.

Another tumor that is known to be MSI-high includes colorectal cancer, she explains. In the gynecologic field, uterine cancers seem to be the tumor type that have MSI-high characteristics. However, early research suggest that some ovarian cancers may have this, as well.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Redefining Ovarian Cancer Treatment Paradigms by Maximizing Therapeutic Outcomes with PARP InhibitorsSep 29, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x